Health News

Vertex Pharmaceuticals Incorporated today announced interim results from the first part of a Phase 2 study designed to evaluate multiple combination regimens of VX-770 and VX-809, Vertex’s lead medicines in development that aim to treat the defective protein that causes cystic fibrosis.

Read more

Filed under: Pharmacy News
Tags: medicine, Pharmacy, Protein

Related posts

• Xeomin® (incobotulinumtoxinA) Data To Be Presented At The 71st Annual Assembly Of The American Academy Of Physical Medicine And Rehabilitation (0)
  Merz Pharmaceuticals announced that data from stability and clinical studies evaluating Xeomin® (incobotulinumtoxinA), a botulinum toxin type A free from accessory proteins, will be presented at the 71st Annual Assembly of the American Academy of Physical Medicine and Rehabilitation (AAPM&R) in Seattle, Wash. The U.S... Read more [tags] Pharmacy News [/tags]
  
  
• Vertex VX-770 Phase 3 STRIVE study for cystic fibrosis demonstrates improvements in lung function (0)
  Vertex Pharmaceuticals Incorporated today announced the final results from its pivotal Phase 3 STRIVE study that evaluated VX-770, a medicine in development that targets the defective protein that causes cystic fibrosis (CF). Read more [tags] Pharmacy News [/tags]
  
  
• Synthetic Biologists Use Software To Customize Protein Production (0)
  A software program developed by a Penn State synthetic biologist could provide biotechnology companies with genetic plans to help them turn bacteria into molecular factories, capable of producing everything from biofuels to medicine. "It's similar to how an engineer designs a plane or a car," said Howard M... Read more [tags] Pharmacy News [/tags]
  
  
• Study links loss of PTEN gene with patient’s response to melanoma therapy (0)
  Genetic analysis of the tumors from patients with advanced melanoma can clue researchers in to how well patients will respond to a therapy that targets the growth-promoting protein called BRAF, a researcher from the Perelman School of Medicine at the University of Pennsylvania will report on Monday, June 6 at the annual meeting of the [...]
  
  
• Study finds broader statin use as a cost-effective way to prevent heart attack and stroke (0)
  A new analysis suggests that broader statin use among adult patients may be a cost-effective way to prevent heart attack and stroke. The Stanford University School of Medicine study also found that using a popular test - a screening for high sensitivity C-reactive protein, or CRP - to identify patients who may benefit from statin [...]